Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants-Reference-Cited by-同舟云学术

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants

Published:2022-06-06 Issue:5 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Bajoria Sakshi¹,Kaur Kawaljit¹,Kumru Ozan S.¹,Van Slyke Greta²,Doering Jennifer²,Novak Hayley²,Rodriguez Aponte Sergio A.³⁴,Dalvie Neil C.⁴⁵,Naranjo Christopher A.⁴,Johnston Ryan S.⁴,Silverman Judith Maxwell⁶,Kleanthous Harry⁶,Love J. Christopher⁴⁵,Mantis Nicholas J.²^ORCID,Joshi Sangeeta B.¹,Volkin David B.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA

2. Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA

3. Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA

4. The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

5. Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA

6. Bill & Melinda Gates Foundation, Seattle, WA, USA

Funder

Bill & Melinda Gates Foundation

National Cancer Institute of the National Institutes of Health

National Institute for Innovation in Manufacturing Biopharmaceuticals

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2079346

Reference77 articles.

1. COVID-19 vaccine tracker and landscape [Internet]. World Health Organization; [accessed 2021 Aug 23]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

2. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

3. Director-General’s opening remarks at the media briefing on COVID-19 – 9 April 2021 [Internet]; [accessed 2021 Aug 28]. https://www.who.int/director-general/speeches/detail/director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-9-april-2021.

4. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy

5. The promise of mRNA vaccines: a biotech and industrial perspective

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants;Biomaterials;2024-07

2. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization;Immunity, Inflammation and Disease;2024-07

3. Immunogenicity of different nanoparticle adjuvants containing recombinant RBD coronavirus antigen in animal model;Biotechnology and Applied Biochemistry;2023-11-30

4. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines;Vaccine;2023-10

5. Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate;Molecular Therapy - Methods & Clinical Development;2023-09